Q: If you were to define the greatest achievement of your scientific work so far?
The discovery of the actions of neuronal nitric oxide synthase (NOS1) in the myocardium. We first identified its effect on calcium handling and myocardial relaxation; then we discovered its relationship with voltage-dependent potassium currents and, most recently, its link to glucose transport and metabolism. We now know that myocardial NOS1 is a therapeutic target for a variety of cardiovascular diseases -such as left ventricular hypertrophy, diabetic cardiomyopathy, and atrial fibrillation.
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Q:
What would you say is the most promising discovery in basic cardiovascular science? And do you think it brings promise for future cardiovascular therapies?
Several years' worth of work on genome-wide association studies has highlighted the role of genetics for refining risk stratification, and for the identification and validation of new therapeutic targets. Other important discoveries are gene editing and RNA interference; I predict these will have important therapeutic applications in the treatment of both inherited and acquired conditions in the near future.
Q: Do you think basic science can ever compete with clinical research in the eyes of the public?
Yes, it all depends on how it is communicated. Communicating basic science discoveries is challenging because it is often difficult to predict what the practical applications of the findings will be in the short-term. Yet, fundamental discovery drives the future of medicine, society and, ultimately, our species. This needs to come across to the public. Poor methodology. For example, we need to ensure that experiments are appropriately blinded and controlled; that outcomes and data analysis are planned in advance and adhered to, much as one does for a randomized clinical trial. It has been repeatedly stated that only a fraction of the disruptive basic science discoveries published in major journals can be reproduced by industrial labs. This is most likely not due to fraud, but to self-deception made possible by the adoption of weak methodological standards.
Q: Is there a way we can try to speed up the process of translation from basic discoveries?
Novel putative therapeutic targets need to be validated using robust experimental methods and models, including genetics when appropriate. Furthermore, the way we undertake clinical trials needs to change. More pragmatic, less costly clinical trials (such as those undertaken within nation-wide registries, e.g. SWEDE-HEART) would allow investigators and companies to test many more new agents, thereby speeding up the process of translation.
Q: Coming back to the European Society of Cardiology (ESC), which you will be leading for the next years. The ESC is one of the most effective and strongest cardiovascular societies worldwide. What would say are the key factors contributing to its success?
Unity is a major strength of the ESC. Sub-specialty Associations, Working Groups and Councils are all working together within the ESC. I see them as incubators for novel ideas they can test and try rapidly. Common values but operational flexibility are ingredients for success in any organization. Our strength also comes from collective decision making and representation; the ESC leadership is elected by the ESC members and what the ESC puts forward is discussed and validated by 57 National Cardiac Societies.
Q: Considering the current size and strength of the European Society of Cardiology, how would you like to see it grow further? What are your biggest ambitions for the Society in the coming years?
The ESC can definitely increase its scope in advocacy and research. To this end, we have now established the ESC Patient Forum, appointed an Advocacy Director at the ESC Brussels Office, and established a Research Committee which will provide both strategic contents and peer-review for all projects submitted to the ESC. Overall, my most important objective is to see the ESC evolve from a society of 'cardiologists for cardiologists' to an institution that also reaches out to patients, citizens, and policy makers.
Q: Speaking of changes or evolution within big organizations like the European Society of Cardiology, what is your philosophy on change? Should it be rapid, or slow and gradual?
If you had asked me 10 years ago, I would have said that slow, progressive change was preferable. I now think that advocating for slow progress may be a way of abdicating one's responsibilities. In other words, where there has been stalemate for a while e.g., women's career in cardiology, one needs a revolution. I have learnt that progress is usually resisted, both because of inertia and, importantly, because the status quo protects itself and its modus operandi. 
